scholarly journals An ELISA-based high throughput protein truncation test for inherited breast cancer

2010 ◽  
Vol 12 (5) ◽  
Author(s):  
Mark J Lim ◽  
Gabriel J Foster ◽  
Sadanand Gite ◽  
Heather P Ostendorff ◽  
Steven Narod ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
Protein Truncation Test ◽  
Inherited Breast Cancer ◽  
Protein Truncation

Mutation Detection in the Breast Cancer Gene BRCA1 Using the Protein Truncation Test

2000 ◽  
Vol 14 (2) ◽  
pp. 89-98 ◽  
Author(s):  
Wendy Moore ◽  
Irina Bogdarina ◽  
Umesh A. Patel ◽  
Michael Perry ◽  
Colyn Crane-Robinson
Keyword(s):  
Breast Cancer ◽  
Mutation Detection ◽  
Cancer Gene ◽  
Protein Truncation Test ◽  
Protein Truncation ◽  
Breast Cancer Gene

scholarly journals Erratum: A high-throughput nonisotopic protein truncation test

2003 ◽  
Vol 21 (9) ◽  
pp. 1098-1098
Author(s):  
Sadanand Gite ◽  
Mark Lim ◽  
Rick Carlson ◽  
Jerzy Olejnik ◽  
Barbara Zehnbauer ◽  
...  
Keyword(s):  
High Throughput ◽  
Protein Truncation Test ◽  
Protein Truncation

A high-throughput nonisotopic protein truncation test

2003 ◽  
Vol 21 (2) ◽  
pp. 194-197 ◽  
Author(s):  
Sadanand Gite ◽  
Mark Lim ◽  
Rick Carlson ◽  
Jerzy Olejnik ◽  
Barbara Zehnbauer ◽  
...  
Keyword(s):  
High Throughput ◽  
Protein Truncation Test ◽  
Protein Truncation

scholarly journals Selection of aptamers against triple negative breast cancer cells using high throughput sequencing

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Débora Ferreira ◽  
Joaquim Barbosa ◽  
Diana A. Sousa ◽  
Cátia Silva ◽  
Luís D. R. Melo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
Triple Negative Breast Cancer ◽  
High Throughput Sequencing ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Target Cells ◽  
Cancer Tissue ◽  
Surface Receptors

AbstractTriple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced and the 25 most frequent sequences were aligned for homology within their variable core region, plotted according to their free energy and the key nucleotides possibly involved in the target binding site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells with $$K_{d}$$ K d values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively, were further validated. The binding analysis clearly showed their specificity to MDA-MB-231 cells and suggested the targeting of cell surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is a promising candidate to be used in triple-negative breast cancer treatment and/or diagnosis.

Excavating the pathogenic gene of breast cancer based on high throughput data of tumor and somatic reprogramming

Cell Cycle ◽  
2021 ◽  
pp. 1-15
Author(s):  
Lian Duan ◽  
Zhendong Wang ◽  
Xin Zheng ◽  
Junjian Li ◽  
Huamin Yin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Throughput ◽  
High Throughput Data ◽  
Pathogenic Gene
Sign in / Sign up

Export Citation Format

Share Document